IP Library Granted Patent US 8,778,404
Granted Patent B2
US 8,778,404 · App. 12/475,482 · Granted Jul 15, 2014

Nutritional compositions

Inventors: Hisae Kume (Kanagawa, JP); Makoto Yamaguchi (Kanagawa, JP); Kenji Mizumoto (Kanagawa, JP); Hajime Sasaki (Kanagawa, JP)
Assignee: Meiji Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,778,404
App. No.
12/475,482
Granted
Jul 15, 2014
Kind
B2
Abstract

The present inventors discovered that the onset of galactosamine hepatopathy is suppressed by nutritional compositions comprising as essential ingredients: whey protein hydrolysates; lecithin and oils and fats high in oleic acid, which are able to improve the lipid metabolism; and palatinose having an insulin-sparing effect. Furthermore, the whey protein hydrolysate included in the nutritional compositions was found to suppress endotoxin-induced TNF-a and interleukin 6 (IL-6) production in macrophages.

Claims (24)

1. A nutritional composition for liver disease patients who have not undergone surgery comprising:

a) protein, wherein the protein comprises (i) a milk protein hydrolysate selected from the group consisting of whey protein hydrolysate, whey protein concentrate (WPC) hydrolysate, and whey protein isolate (WPI) hydrolysate in an amount of 0.9 to 3 g per 100 mL of the composition and (ii) protein derived from fermented milk in an amount of 2.5 to 4.5 g per 100 mL of the composition;

b) lipids, wherein the lipids comprise an oleic acid-containing oil and lecithin, wherein the lecithin is milk lecithin or soybean lecithin, or both; and

c) carbohydrate, wherein the carbohydrate comprises palatinose in an amount of 4 to 15 g per 100 mL of the composition.

2. The nutritional composition according to claim 1 , wherein said fermented milk-derived protein is from a composition wherein whey in the fermented milk has been reduced.

3. The nutritional composition according to claim 1 , wherein said fermented milk-derived protein is from fresh cheese.

4. The nutritional composition according to claim 3 , wherein said fresh cheese is quark.

5. A nutritional composition for liver disease patients and/or patients under high levels of invasive stress whose concentration of inflammatory cytokines in blood is at a predetermined concentration or more, wherein said nutritional composition comprises:

a) protein, wherein the protein comprises (i) a milk protein hydrolysate selected from the group consisting of whey protein hydrolysate, whey protein concentrate (WPC) hydrolysate, and whey protein isolate (WPI) hydrolysate in an amount of 0.9 to 3 g per 100 mL of the composition and (ii) protein derived from fermented milk in an amount of 2.5 to 4.5 g per 100 mL of the composition;

b) lipids, wherein the lipids comprise an oleic acid-containing oil and lecithin, wherein the lecithin is milk lecithin or soybean lecithin, or both; and

c) carbohydrate, wherein the carbohydrate comprises palatinose in an amount of 4 to 15 g per 100 mL of the composition.

6. The nutritional composition according to claim 5 , wherein said fermented milk-derived protein is from a composition in which the whey in the fermented milk has been reduced.

7. The nutritional composition according to claim 5 , wherein said fermented milk-derived protein is from fresh cheese.

8. The nutritional composition according to claim 7 , wherein said fresh cheese is quark.

9. A method for providing nutrition to a liver disease patient, a liver disease patient who has not undergone surgery and/or a patient under high level of invasive stress whose concentration of inflammatory cytokines in blood is at a predetermined concentration or more, wherein said method comprises administering to such a patients an effective amount of the nutritional composition as set forth in claim 1 .

10. The method of claim 9 , wherein the patient has liver cirrhosis.

11. The method of claim 9 , wherein the patient has hepatic failure.

12. The method, according to claim 9 , wherein said fermented milk-derived protein is from a composition wherein whey in the fermented milk has been reduced.

13. The method, according to claim 9 , wherein said fermented milk-derived protein is from fresh cheese.

14. The method, according to claim 13 , wherein said fresh cheese is quark.

15. A method for providing nutrition to a liver disease patient who has not undergone surgery and/or a patient under high level of invasive stress whose concentration of inflammatory cytokines in blood is at a predetermined concentration or more, wherein said method comprises administering to such a patient an effective amount of the nutritional composition as set forth in claim 5 .

16. The method, according to claim 15 , wherein said fermented milk-derived protein is from a composition wherein whey in the fermented milk has been reduced.

17. The method, according to claim 15 , wherein said fermented milk-derived protein is from fresh cheese.

18. The method, according to claim 17 , wherein said fresh cheese is quark.

Assignments (1)
CHANGE OF NAME Recorded Nov 17, 2011
From: MEIJI DAIRIES CORPORATION
To: MEIJI CO., LTD.
Reel/Frame 027244/0433 →
Priority Claims (1)
JP 2002-339948 · Nov 22, 2002 · national
Continuity (2)
Continuation 10535585
Related Publication 20090233865A1 · Sep 17, 2009